tipranks.comSEP 141 min read$CEVA

Ceva upgraded to Buy at StoneX following recent selloff

StoneX upgraded Ceva to Buy from Hold, setting a $42 price target. The firm cited a 30% share price decline since mid-July and potential upside for FY27 and FY28. The analyst also noted possible revenue acceleration as a catalyst.

Original reporting

tipranks.com

Published Sep 14, 2026, 11:27 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 14, 2026, 3:10 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Ceva upgraded to Buy at StoneX following recent selloff — source image — Source · tipranks.com

Decision brief

The 30-second read

$CEVABullishMed

Why it matters

The upgrade provides a fresh catalyst that could drive the stock toward the $42 target, offering a buying opportunity for traders.

Market read

The upgrade is a primary piece of company news that may influence Ceva's price action and sector sentiment.

What to watch

Potential regulatory risks and competition are not addressed in the upgrade.

Relevance 7/10Novelty 7/10Timing: today

Background

Ceva, a US-listed biotech, received an upgrade from StoneX after a 30% selloff since mid-July.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CEVABullishMedium confidence

Context

StoneX upgraded Ceva to Buy from Hold with a $42 price target, citing recent selloff and catalysts.

Expected impact

Share price may rise toward the $42 target.

Evidence & confidence

Upgrade is based on recent selloff, revenue acceleration expectations and FY27/FY28 upside scenario.

Market effects

Sector

Biotech sector may see modest uplift as analyst upgrades signal confidence in pipeline.

Regional

US biotech stocks could benefit from the positive sentiment.

Global

Limited to investors tracking US-listed biotech companies.

Counterpoint

What could challenge this read

The upgrade may be premature if upcoming trial data disappoints.

Key entities

Company
Ceva
US biotech firm (ticker CEVA).
Research Firm
StoneX
Analyst firm that issued the upgrade.

Read at source ← All news

SEP 17

$SNEXMed

StoneX (SNEX) Turns Mortgage Bond Complexity Into New Revenue

StoneX Group (SNEX) launched a synthetic credit structure with DeltaTerra for mortgage bonds, enabling institutional investors to gain exposure via credit default swaps. The company reported strong fiscal Q3 results, with revenue up 47% and net income more than doubling. Growth was driven by commercial and institutional segments, while retail segment revenue declined. Interest expenses and variable costs increased, and a new structured product aims to capitalize on a market event. Hedge funds ha

insidermonkey.com2 min

SEP 11

$XYZMed

Positive Report for Block (XYZ) from StoneX

StoneX upgraded Block (XYZ) to Buy with a $105 price target. Goldman Sachs also gave a Buy rating, while Scotiabank initiated coverage with a Hold. Block reported Q2 revenue of $6.62B and net profit of $88.52M, up from $6.05B and $538.46M last year.

theglobeandmail.com1 min

SEP 9

$HOODMed

StoneX Financial’s Coverage Of Robinhood $HOOD Stock Anticipates Software-Like Growth Beyond Crypto Trading

StoneX Financial initiated coverage of Robinhood Markets with a Buy rating and $170 price target, implying 45% upside. Analyst Mark Palmer cited accelerating growth trends, including Q2 net revenue up 32% YoY to $1.31B. Crypto revenue dropped 38% but now represents 8% of net revenue. Palmer highlighted Robinhood's expansion into exchange platforms and blockchain infrastructure, with Robinhood Chain's launch and strong fee collections. Prediction markets also showed significant growth, with Q2 re

crowdfundinsider.com2 min

SEP 4

$XPOHighAI 8/10

XPO stock reaffirmed at Buy by StoneX on strong LTL trends

StoneX reaffirmed a Buy rating and $240 price target on XPO, citing strong LTL trends and pricing discipline. XPO's Q2 2026 earnings beat estimates, with revenue up 13% YoY. Moody's upgraded XPO's rating to Ba1, while BofA maintained a Buy rating but lowered its target to $228. XPO's stock is up 36% YTD, with a market cap of $22.46B.

investing.com2 min

SEP 4

$PHMMed

PulteGroup stock initiated with buy rating at StoneX, $148 target

StoneX initiated coverage on PulteGroup (NYSE:PHM) with a buy rating and $148 target, citing 10% CAGR, 15% ROE, and strong margins. PHM trades at a P/E of 12.68, deemed undervalued. Q2 2026 earnings beat estimates with $2.48 EPS on $3.98B revenue. Wolfe Research and Citizens also issued positive ratings. NAHB's Housing Market Index rose to 35 in August 2026.